The importance of early therapy intensification in B-cell CLL (B-CLL) patients remains to be defined. Even though several studies have been published, no randomized trials comparing directly autologous stem cell transplant (ASCT) and the accepted conventional therapy (that is, rituximab, fludarabine and CY; R-FC) have been reported so far. To assess the benefit of a first-line aggressive therapy, we designed a multicenter, randomized, phase 3 trial comparing R-FC and high-dose chemotherapy supported by ASCT in patients under 65 years of age, with stage B(II) or C B-CLL. Primary end point was CR: 96 patients were enrolled (48 in each arm). On an intent-to-treat basis, the CR rates in the ASCT and R-FC arms were 62.5% and 58%, respectively. After 5 years of follow-up, PFS was 60.4% in the ASCT arm and 65.1% in the R-FC arm, time to progression 65.8 and 70.5%, and overall survival 88% vs 88.1%, respectively. Our trial demonstrates, for the first time in a randomized manner, that frontline ASCT does not translate into a survival advantage when compared with benchmark chemoimmunotherapy in B-CLL patients; the possibility of its clinical benefit in certain subgroups remains uncertain.
INTRODUCTION
B-CLL is the most common form of leukemia in adults in western countries and it is characterized by the slow, albeit continous, accumulation of mature B lymphocytes in peripheral blood, BM and lymphoid organs. Although the median age of 70 years at diagnosis does not allow intensive chemotherapy regimens and achieving a prolonged disease control is the best option, at least 30% of the patients are younger than 65 years, 1 thus deserving a more aggressive approach. Several groups reported results with standard-dose chemotherapy or with intensive therapeutic regimens: the evidence is that R-FC chemoimmunotherapy is to be considered the gold standard for B-CLL treatment, while more aggressive approaches do not translate into a survival advantage. 2 However, in spite of the large number of reports, 3, 4 randomized trials comparing R-FC and autologous stem cell transplant (ASCT) are still lacking while there is recent evidence supporting the use of R-FC in the front-line setting. 5 Since ASCT appears to be a reasonably safe procedure, and ASCT trials performed so far are difficult to compare for differences in myeloablative regimens, use of MoAbs, graft purging and type of chemotherapy, [6] [7] [8] [9] we started a multicenter, randomized, phase 3 trial comparing R-FC and highdose chemotherapy supported by ASCT in patients under 65 years of age, with stage B(II) or C B-CLL in 2005. The aim was to study the feasibility of early therapeutic intensification and compare its efficacy with the best therapeutic option available.
PATIENTS AND METHODS

Trial design
This was an italian multicenter, prospective, randomized, parallel-group study. Treatment was allocated centrally by the Michelangelo Operations Office, using a minimization algorithm described by Taves 10 with stratification for deletion of 11q13, deletion of 17p13, immunoglobulin variable region (IGVH) mutation. Patients were randomly assigned in a ratio of 1:1 to one of the two treatment arms.
Patients
Between April 2005 and January 2010, 96 patients with B-CLL were randomized to receive either rituximab in combination with CY and fludarabine (R-FC group) or high-dose sequential (R-HDS) chemotherapy with ASCT (R-HDS group). Eligibility criteria included written informed consent; age of 65 years or younger; absence of severe organ dysfunction not due to tumor; no previous viral infections; a histologically confirmed Binet B(II) or C stage B-CLL, either at diagnosis or relapse after 412 months since first-line polychemotherapy; expression of CD20 by neoplastic cells; availability of a molecular probe for PCR amplification of DNA to assess minimal residual disease (MRD); deletion of 11q13 or 17p13 or IGVH 1 mutation rate o2%. Characteristics of patients are listed in Table 1 . The trial was approved by each of the participating centers' ethics committee; all participants gave written informed consent.
Treatment plan
Conventional treatment (R-FC group) consisted of six courses of rituximab 375 mg/sm i.v. on day 1, fludarabine 30 mg/sm and CY 300 mg/sm i.v. from day 2 to day 4 (after the first course, rituximab was administered at 500 mg/sm) (Figure 1 ). After the first four courses, all patients received intermediate-dose CY (4 g/sm; hd-CTX), followed by two doses of rituximab, with the aim to mobilize hematopoietic stem cells (HSCs). Patients enrolled in the R-HDS group were treated, after an initial phase consisting of one cycle of adryamicin prednisone vincriarine chemotherapy (doxorubicin 75 mg/sm on day 1, vincristine 1.4 mg/sm on day 1 and prednisone 75 mg from day 1 to day 14) and two cycles of DHAP chemotherapy (cisplatin 100 mg/sm, continous infusion, on day 1, cytarabine 2 g/sm every 12 h on day 2 and dexamethasone 40 mg from day 1 to day 4), with a rituximab-supplemented three-step high-dose sequence including high-dose CY (7 g/sm; HD-CTX), high-dose cytarabine (2 g/sm every 12 h, days 1 to 6; HD-araC), and fludarabine (25 mg/sm from day 1 to day 5) plus high-dose melphalan (140 mg/sm on day 6; FM). The choice of the combination of fludarabine and melphalan as myeloablative therapy was based on our previous experience with other melphalanbased therapy (such as mitoxantrone and melphalan): reasons for the substitution of mitoxantrone with fludarabine were (i) to avoid the potential cardiotoxicity of mitoxantrone and (ii) to use a drug with a wellknown activity in B-CLL. In this group, rituximab was infused for a total of six doses: twice after CY, twice after cytarabine and twice during the final myeloablative step. All R-FC and R-HDS patients received four weekly final doses of rituximab (500 mg/sm) after the last chemotherapy cycle.
To hasten hematopoietic recovery and reduce hematologic toxicity, each R-HDS patient received two HSC reinfusions, the first after the myelotoxic course of HD-araC (ASCT #1), and the second after the myeloablative course of FM (ASCT #2). The minimum target dose of HSCs per kg of body weight to be reinfused after each of the two autografts were 2 Â 10 6 and 5 Â 10
6
, respectively. The use of granulocyte-colony stimulating factors was allowed for mobilization of HSCs after HD-CTX, HD-araC and hd-CTX, and after the final myeloablative chemotherapy in the R-HDS group and for support, in all other cases.
Monitoring, harvesting and processing of HSCs HSCs in peripheral blood were assessed by counting total CD34 þ cells by flow cytometry with the CD34 Ab (Becton Dickinson, San Jose, CA, USA) as previously described. 11 Leukaphereses 12 were performed during growthfactor-expanded mobilization of HSCs occurring after administration of either HD-CTX, HD-araC or both in the R-HDS arm and after hd-CTX in the R-FC arm. The progenitor cells to be autografted were processed, cryopreserved, thawed and reinfused as previously described. 13 Molecular monitoring of MRD Monitoring of MRD was accomplished by assessing DNA samples from peripheral blood, BM and HSCs with the use of semi-nested, qualitative, PCR amplification of clonal rearrangement of IgH genes, as described elsewhere.
14, 15 The limit of detection of MRD was reproducible at the level of 10
Assessment of response CR and PR were defined according to recommendations. 15 Molecular CR was defined as the absence of neoplastic cells within BM as demonstrated by PCR assay. Toxicity was evaluated according to the WHO criteria.
Statistical analysis
The primary aim of the study was to compare the rate of CR in the two treatment arms. The number of patients needed was 96 for a wo-sided significance level of 5% and power of 80% to show a statistically significant increment of 30%.
The significance of differences among the different groups was calculated with the non-parametric Mann-Whitney U-test or t-test, as appropriate. High-dose chemotherapy in CLL M Magni et al Secondary aims were PFS, time to progression (TTP), overall survival (OS) and MRD assessment in the BM at the end of treatment. PFS was measured from randomization to the occurrence of progressive disease (PD), relapse and death from all causes. TTP was measured from randomization to the occurrence of PD or relapse. OS was measured from randomization until death. All randomly assigned patients were included in efficacy analyses, which were conducted on an intent-to-treat basis. Chi-square tests for categorical data and log-rank tests for time-to-event end points provided two-sided P-values. Kaplan-Meier curves were used to estimate 5-year rates and 95% confidence limits. 16 Safety population is defined as all randomized patients who received at least one dose of either treatment, and patients were classified according to the treatment administered, regardless of any discrepancy with respect to the treatment they were randomized to.
RESULTS
Baseline characteristics
Between April 2005 and January 2010, 96 patients with newly diagnosed or first relapse B-CLL were randomized to receive either R-FC group or R-HDS chemotherapy with ASCT (R-HDS group). Although the majority of patients was chemotherapy naive at study entry, six patients (13%) in each arm had received previous chemotherapy (fludarabine or alkylating agents were allowed with a disease-free interval X1 year) ( Table 1) .
Allocation and treatment
Rituximab in combination with high-dose sequential. Forty-six of the 48 enrolled patients underwent initial cytoreduction with induction chemotherapy (1 patient withdrew the consent and 1 patient was misdiagnosed); 41 patients proceeded to HD-CTX, while 5 patients discontinued the treatment for various reasons (2 for PD, 2 for safety reasons, 1 on investigator's decision) ( Figures  1 and 2) . After HSC harvest, 36 patients completed HD-araC treatment; 5 patients were excluded: 2 for PD, 2 for safety and 1 for medical decision. After the second HSC collection, 31 patients concluded the whole treatment with ASCT (5 patients did not proceeded to ASCT: 1 for PD, 1 on investigator's choice, 2 for safety and 1 for evolution to Richter's syndrome). After ASCT, 30 patients received the four planned rituximab doses (1 patient progressed shortly after ASCT).
Rituximab, fludarabine and CY. Forty-five of the 48 enrolled patients were initially treated with four R-FC cycles (3 patients did not enter the protocol: 1 withdrew the consent and 2 were misdiagnosed). Forty-one patients were treated with hd-CTX: 4 patients did not proceed to this phase of treatment for safety reasons (3 patients) and PD (1 patient). Thirty-six patients concluded the treatment with two more cycles of R-FC: 5 patients discontinued the treatment after hd-CTX (all for safety); finally, 34 patients entered the follow up phase (1 patient discontinued the treatment for infection and 1 for toxicity). The treatment for both groups was concluded with four final doses of rituximab. Median duration of treatment in both arms was about 6 months.
HSCs mobilization
Among the 48 patients in the R-HDS arm, 31 patients were harvested after HD-CTX and 24 after HD-araC. Only 36% of HSC collections were MRD-negative after HD-CTX, while this percentage reached 57% after HD-araC. Mean CD34 þ cell count was 6.3 Â 10 6 /kg (range 1.0-23.0 Â 10 6 /kg) after HD-CTX and 14.7 Â 10 6 /kg (range 2.0-38.0 Â 10 6 /kg) after HD-araC. As already reported by others, 17, 18 HSC collection in patients receiving fludarabine was successful in a minority of cases: only five patients mobilized after hd-CTX, with a mean CD34 þ cell count of 6 Â 10 6 /kg (range 1.0-7.0 Â 10 6 /kg). Only 13% of the HSC harvests obtained in the R-FC group were MRD-negative.
Response rate A total of 31 patients received the whole treatment in the R-HDS arm, while 34 patients completed all the six planned cycles of therapy in the R-FC arm (Figure 3) . R-HDS patients obtained CR in the 62.5% of the cases and PR in 6% of the cases, for an overall response rate of 68.5%; patients receiving R-FC had a 58% CR rate and a 15% PR rate, for an overall response rate of 73%. PD was reported in 15% of R-HDS patients and 8% of R-FC patients, while 16% of R-HDS and 19% of R-FC patients could not be assessed for response. The observed CR rate failed to significantly demonstrate the anticipated benefit for the R-HDS regimen.
The second end point was to assess the difference of MRD in the BM: at the end of whole treatment, we could not detect any difference between the two groups, with a disease-free BM in 54% of R-HDS patients and 52% in R-FC patients (P ¼ 0.88).
Follow-up After 5 years of follow-up, PFS is 60.4% for the R-HDS group (95% CL 50.0-80.2) and 65.1% in the R-FC group (95% CL 50.1-80.2), with no statistically significant difference (P ¼ 0.66) (Figure 4) . Also, 5-year TTP (R-HDS 65.8%, 95% CL 50.1-81.4; R-FC 70.5%, 95% CL 55.5-85.6; P ¼ 0.64) and OS (R-HDS 88.0%, 95% CL 78.1-97.9; R-FC 88.1%, 95% CL 78.3-97.9; P ¼ 0.99) were comparable in both groups. In addition, when R-HDS patients were analyzed on the basis of reinfused HPCs (that is, MRD positive vs negative) or molecular status of BM (that is, positive or negative at the end of treatment), we did not find any difference in terms of PFS and OS (data not shown). High-dose chemotherapy in CLL M Magni et al
Adverse events
Rituximab in combination with high-dose sequential. A total of 14 patients in the R-HDS arm discontinued the treatment. After the induction phase, 6 patients stopped the therapy: 2 for PD, 1 for cerebral abscess leading to death, 1 for unacceptable nonhematologic toxicity due to pre-existing co-morbidities, 1 for sepsis and 1 for psychiatric disorder. After HD-CTX, 4 patients were excluded from treatment: 2 for mobilization failure and concomitant PD, 1 for parvovirus infection and 1 for sepsis. Four patients terminated the treatment after HD-araC: 1 for PD, 1 for septic shock leading to death, 1 for prolonged pancytopenia and 1 for Richter's evolution.
Rituximab, fludarabine and CY. In the R-FC arm, 11 patients discontinued the treatment: 1 for PD and 3 for prolonged hematologic toxicity after the fourth R-FC cycle. After hd-CTX, 5 patients were forced to interrupt the treatment: 1 for prolonged neutropenia, 1 for septic shock leading to death, 1 for allergic reaction, 1 for HBV reactivation and 1 for a cerebral ischemic stroke. In the group receiving the two final R-FC cycles, 1 patient died for Pseudomonas aeruginosa infection after the last cycle and 1 stopped the treatment after the fifth R-FC cycle for prolonged hematologic toxicity.
Overall treatment toxicity Grade 3 or 4 hematologic and non-hematologic toxicity is reported in Table 2 : although there were more infectious and fever of unknown origin episodes in the R-HDS group due to the heavier myelosuppression caused by high-dose treatment, this was not significantly different between the two treatment arms. However, only one patient had to interrupt the treatment for prolonged pancytopenia while five patients in the R-FC group had to stop the chemotherapy for hematologic toxicity. There were four treatment-related deaths, two in each group; during the follow-up phase, six more patients have died in the R-HDS group (three for PD and three for infectious episodes) and four in the R-FC group (one for PD, one for Richter's evolution, one for suicide and one for mantle cell lymphoma). Only one case of myelodysplastic syndrome has been reported in the R-FC group.
Registered (n =96)
Analysed (n =48)
Allocated to R-HDS (n =46)
• Received allocated therapy (n =32) • Not meeting inclusion criteria (n =1) • Declined to participate (n =1) • Discontinued therapy (n =14):
Allocated to R-FC (n =45)
• Received allocated therapy (n =34) • Not meeting inclusion criteria (n =2) • Declined to participate (n =1)
• Discontinued terapy (n =11): 
DISCUSSION
To our knowledge, this is the first prospective randomized study addressing the use of ASCT vs R-FC in B-CLL patients. Even though their common origin is still uncertain, [19] [20] [21] clinical, genetic and immunophenotypic similarities between B-CLL and mantle cell lymphoma (namely, presence in the peripheral blood of clonal B lymphocytes, absence of IGVH somatic mutations and expression of common antigens), as well as the very high durable remission rate obtained by our group in the latter patients upon high-dose chemotherapy regimens, 22, 23 encouraged the use of this treatment modality in B-CLL patients. Previous reports 3, 4, 7, 9 suggested the superiority of ASCT over conventional therapy in terms of EFS. However, those results are difficult to compare with ours. In fact, in the vast majority of those studies, the conventional treatment adopted was different from the accepted benchmark therapy currently used for B-CLL, 2, 24 and some were retrospective in nature or limited to patients who had achieved CR or good PR after induction therapy. Our results, obtained comparing upfront the gold standard of conventional therapy with ASCT, have shown that after 5 years of follow-up no difference between the two arms in terms of PFS, TTP and OS could be detected; this, even with limitations depending on the small number of subjects, was valid also when data were analyzed considering the different cytogenetic features. The mean HSC yield obtained in our trial compares favorably with that reported in our previous studies: 22, 25 however, while in vivo purging with rituximab allowed high-rate of MRD-negative harvests in other lymphoproliferative diseases, the same is not true for B-CLL, with a percentage below 60% of MRDnegative harvests. This result might have been expected taking into account the lower level of CD20 Ag expression that has been reported on B-CLL cells 26, 27 and the shorter half-life of rituximab due to the presence of a soluble form of CD20 Ag in the plasma of B-CLL patients. 28 The engrafment with MRD-positive or negative HSCs does not seem to increase the survival rate, even with limitations of the small number of subjects analyzed in our trial. Similar results have already been reported, 4 while a positive correlation between MRD-negative HSCs and survival has been demonstrated by other groups. 29 Finally, failure of HSC mobilization after fludarabine has already been reported in several studies, 17, 18 and our data are in keeping with those findings. Abbreviations: FUO ¼ fever of unknown origin; MDS ¼ myelodysplastic syndromes. *P-value ¼ 0.067; **P-value ¼ 0.21.
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No significant differences in the number of severe adverse events, such as treatment-related deaths, infections and secondary myelodysplastic syndromes were observed between the two treatment groups; in addition, the analysis for some of the events is difficult for the introduction of hd-CTX in the R-FC group. In particular, while other groups have reported secondary myelodysplastic syndromes and secondary tumor rates as high as 7.7% 6 and 15%, 3 respectively, we documented only one case of secondary myelodysplastic syndrome in a patient treated with R-FC: if this is due to the use of fludarabine and melphalan as myeloablative regimen instead of CY and TBI, remains an open issue, 30 but a more likely explanation might lie in the small number of patients and in the short follow up. Our data regarding the risk of infection compares favorably with that reported by Keating and co-workers: 31 in their study, R-FC-treated patients had a 0.12 risk of infection per course of therapy, similar to the 0.13 observed in our series. As might be expected, R-HDS patients experienced a higher risk of infection (0.23), with one case of lethal septic shock.
Although with limitations for the small number of patients analyzed and differently from what reported in other studies, 32 we could not establish a correlation between the molecular status of the BM at the end of treatment and OS. Molecular analysis of BM has been reported in other studies with conflicting results: MRDnegative BM rates at the end of treatment varies between 37% 8 and 80%
6 in ASCT trials. However, low sensitivity and poor standardization of methods between different laboratories 5 call for a more systematic approach in future trials. 32 In conclusion, our study failed to significantly demonstrate the anticipated benefit for the R-HDS regimen over R-FC in terms of CR rate. Despite the limited sample size, the observed similarity in outcome in terms of CR, EFS, TTP and OS for B-CLL patients treated with ASCT or R-FC allow us to argue against the upfront use of high-dose chemotherapy in this diseases. 33 In addition, considering the results recently obtained with new drugs, 34 it is likely that transplant and chemotherapy-based strategy for B-CLL therapy will undergo major changes in the near future.
